Abbott's Q4 MDx Sales Flat Year Over Year | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott Laboratories today reported that its fourth quarter 2013 molecular diagnostics sales were flat year over year as its overall diagnostics sales increased 6 percent.

The firm posted MDx sales of $131 million for the quarter, flat with Q4 2012. It said that foreign exchange trimmed nearly 1 percent off its MDx revenues for the quarter. However, its international MDx sales were up around 10 percent on an operational basis, driven by "continued strong growth in infectious disease testing, particularly in emerging markets."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.